BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch
Biontech Se Sponsored Adr (BNTX) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNTech SE (BNTX) is running a Phase I/IIa trial called “A Randomized, Dose-escalation Phase I/IIa Trial With Controlled Human Malaria Infection to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of an Investigational RNA-based Vaccine for Prevention of P. Falciparum Malaria in Healthy Malaria naïve Adults.” It aims to show whether an RNA-based malaria shot can safely trigger strong protection in adults who have never had malaria, a key step before larger studies.
The core treatment is BNT165e, a multi-antigen RNA vaccine given by injection and designed to prevent P. falciparum malaria. It combines three RNA components that teach the body to recognize the parasite at different stages, while a simple saline placebo is used for comparison.
The study uses a randomized design, so volunteers are assigned by chance to vaccine or placebo groups. It follows a stepwise dose-escalation model with observer blinding, meaning participants and study staff who track outcomes do not know who received the active shot, and the main goal is to see if the vaccine can safely prevent infection.
The trial began in late 2023, marking BioNTech’s formal move into malaria with its mRNA platform. The most recent update was submitted on April 14, 2026, and the study is now listed as completed, indicating dosing and follow-up are done and the focus is shifting toward analyzing data.
For investors, this update supports the view that BioNTech is pushing to diversify beyond COVID-19 into global infectious disease markets. Success here could open a new commercial path in malaria prevention, put competitive pressure on traditional vaccine players, and strengthen sentiment around the broader mRNA vaccine class.
The study is now completed with recent updates recorded, and further details are available on the ClinicalTrials portal.
To learn more about BNTX’s potential, visit the Biontech Se Sponsored Adr drug pipeline page.
